» Articles » PMID: 29187845

Loss of Genome Fidelity: Beta HPVs and the DNA Damage Response

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2017 Dec 1
PMID 29187845
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

While the role of genus alpha human papillomaviruses in the tumorigenesis and tumor maintenance of anogenital and oropharyngeal cancers is well-established, the role of genus beta human papilloviruses (β-HPVs) in non-melanoma skin cancers (NMSCs) is less certain. Persistent β-HPV infections cause NMSCs in sun-exposed skin of people with a rare genetic disorder, epidermodysplasia verruciformis. However, β-HPV infections in people without epidermodysplasia verruciformis are typically transient. Further, β-HPV gene expression is not necessary for tumor maintenance in the general population as on average there is fewer than one copy of the β-HPV genome per cell in NMSC tumor biopsies. Cell culture, epidemiological, and mouse model experiments support a role for β-HPV infections in the initiation of NMSCs through a "hit and run" mechanism. The virus is hypothesized to act as a cofactor, augmenting the genome destabilizing effects of UV. Supporting this idea, two β-HPV proteins (β-HPV E6 and E7) disrupt the cellular response to UV exposure and other genome destabilizing events by abrogating DNA repair and deregulating cell cycle progression. The aberrant damage response increases the likelihood of oncogenic mutations capable of driving tumorigenesis independent of a sustained β-HPV infection or continued viral protein expression. This review summarizes what is currently known about the deleterious effects of β-HPV on genome maintenance in the context of the virus's putative role in NMSC initiation.

Citing Articles

Treatment and Prevention of HPV-Associated Skin Tumors by HPV Vaccination.

Meyer T, Stockfleth E Vaccines (Basel). 2025; 12(12.

PMID: 39772099 PMC: 11680430. DOI: 10.3390/vaccines12121439.


Cutaneous human papillomavirus E6 impairs the cGAS-STING pathway.

Tolbert E, Dacus D, Pollina R, Wallace N bioRxiv. 2024; .

PMID: 39677810 PMC: 11642751. DOI: 10.1101/2024.11.29.625575.


Human Papillomavirus-Associated Giant Clear Cell Acanthoma and Squamous Cell Carcinoma: A Rare Case Report and Literature Review.

Cuomo R, Rozen W, Pentangelo P, Ceccaroni A, Alfano C, Seth I J Clin Med. 2024; 13(9).

PMID: 38731009 PMC: 11084788. DOI: 10.3390/jcm13092482.


The cutaneous beta human papillomavirus type 8 E6 protein induces CCL2 through the CEBPα/miR-203/p63 pathway to support an inflammatory microenvironment in epidermodysplasia verruciformis skin lesions.

Vella L, Sternjakob A, Lohse S, Fingerle A, Sperling T, Wickenhauser C Front Cell Infect Microbiol. 2024; 14:1336492.

PMID: 38510961 PMC: 10953690. DOI: 10.3389/fcimb.2024.1336492.


Interactions among human papillomavirus proteins and host DNA repair factors differ during the viral life cycle and virus-induced tumorigenesis.

Wendel S, Wallace N mSphere. 2023; 8(6):e0042723.

PMID: 37850786 PMC: 10732048. DOI: 10.1128/msphere.00427-23.


References
1.
Buitrago-Perez A, Hachimi M, Duenas M, Lloveras B, Santos A, Holguin A . A humanized mouse model of HPV-associated pathology driven by E7 expression. PLoS One. 2012; 7(7):e41743. PMC: 3402432. DOI: 10.1371/journal.pone.0041743. View

2.
Sakakibara N, Mitra R, McBride A . The papillomavirus E1 helicase activates a cellular DNA damage response in viral replication foci. J Virol. 2011; 85(17):8981-95. PMC: 3165833. DOI: 10.1128/JVI.00541-11. View

3.
Moy R . Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 1999; 42(1 Pt 2):8-10. DOI: 10.1067/mjd.2000.103343. View

4.
de Koning M, Weissenborn S, Abeni D, Bouwes Bavinck J, Euvrard S, Green A . Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma. J Gen Virol. 2009; 90(Pt 7):1611-1621. DOI: 10.1099/vir.0.010017-0. View

5.
Patel D, Huang S, Baglia L, McCance D . The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 1999; 18(18):5061-72. PMC: 1171577. DOI: 10.1093/emboj/18.18.5061. View